MedPath

Tagged News

Federal Circuit Ruling Limits Patent Protection for Machine Learning Applications, Highlights Trade Secret Alternative

AI
  • The Federal Circuit in Recentive Analytics v. Fox Corp. ruled that applying generic machine learning techniques to known problems without technical innovation is insufficient for patent eligibility under Section 101.
  • The court emphasized that simply automating human tasks with machine learning or improving speed and efficiency does not render claims patent eligible without underlying technological improvements.
  • The decision may drive companies toward trade secret protection for AI innovations, as trade secrets offer broader protection for machine learning applications including training data, model weights, and configuration methods.
  • Patent applicants in the machine learning space must now clearly demonstrate technical improvements to the ML models themselves rather than merely claiming new applications of existing techniques.

Mana.bio Unveils AI-Driven Advances in RNA Delivery at ASGCT 2025

AIOncology
  • Mana.bio presented three posters at ASGCT 2025 showcasing their machine learning platform for designing lipid nanoparticles with improved safety and tissue specificity for RNA therapeutics.
  • The company demonstrated significant progress in developing precision RNA therapies targeting T-cells and lung tissue, addressing key challenges in extra-hepatic RNA delivery.
  • By combining public and laboratory-generated data, Mana.bio's AI models can predict critical LNP attributes including physiochemical properties, tissue specificity, and in-vivo safety profiles.

Cardiothoracic Surgeon Emphasizes Human Resources as Key to AI-Driven Cardiovascular Care Transformation

AI
  • Antoine Keller, MD, cardiothoracic surgeon and founder of HeartSense, highlights the transformative potential of artificial intelligence and digital auscultation in cardiovascular care delivery.
  • The technology enables more accessible cardiovascular assessments and screening for underserved rural communities in Louisiana, addressing significant geographical barriers to quality care.
  • Despite AI's ability to identify care gaps through electronic medical record data mining, Keller emphasizes that skilled human resources remain the critical factor for effective implementation.
  • The physician advocates for increased investment in data science-trained healthcare professionals to fully leverage AI capabilities and improve cardiovascular health equity.

PanGIA Biotech to Present AI-Driven Urine-Based Prostate Cancer Detection Platform at ASCO 2025

AI
  • PanGIA Biotech will present collaborative research on AI-enabled prostate cancer prediction using urine-based liquid biopsy at ASCO 2025 in Chicago.
  • The presentation highlights the company's AI-driven diagnostic platform that integrates biomolecular pattern analysis and machine learning for non-invasive cancer detection.
  • The PanGIA® platform is designed to detect and monitor cancers as early as Stage 1 using urine-based biomolecular profiling powered by machine learning algorithms.

X-Chem and Orion Pharma Expand Collaboration to Accelerate Small Molecule Drug Discovery

Drug DiscoveryAIOncology
  • X-Chem and Orion Pharma have expanded their strategic collaboration from hit identification to candidate selection, leveraging DNA-encoded library technology and AI-driven approaches for multiple early-stage programs.
  • The new Technology Access Agreement enables Orion to utilize X-Chem's integrated discovery capabilities, including DEL screening, AI-driven hit triage, and medicinal chemistry support to advance small molecule discovery.
  • This partnership combines X-Chem's ArtemisAI platform with computational and medicinal chemistry expertise to help partners make informed decisions earlier in the discovery process, reducing risk and improving outcomes.

Sapient Launches DynamiQ: Next-Generation Multi-Omics Platform Set to Transform Drug Discovery and Development

Precision MedicineDrug DiscoveryAI
  • Sapient has launched DynamiQ Insights Engine, an advanced multi-omics and real-world data platform that integrates thousands of protein, metabolite, lipid, and cytokine measures with matched genomic and clinical data.
  • The platform contains data from over 56,000 samples collected across multiple timepoints from diverse individuals, making it one of the most deeply phenotyped longitudinal datasets available for biomarker discovery and drug development.
  • DynamiQ's ability to track molecular changes over time alongside clinical outcomes enables researchers to better understand disease subtypes, predict treatment responses, and identify patients most likely to benefit from specific therapies.

Flatiron Health to Showcase AI-Powered Real-World Oncology Data Research at ISPOR 2025

Real World EvidenceAIOncologyPrecision Medicine
• Flatiron Health will present over 15 research studies at ISPOR 2025, demonstrating how machine learning and AI can transform real-world oncology data into valuable evidence for regulatory decisions.
• Key presentations include validation of ML-extracted response data from EHRs, analysis of real-world evidence acceptance by FDA and EMA, and introduction of a novel Japanese breast cancer database.
• The company's research highlights the growing importance of real-world data in complementing traditional clinical trials and informing precision medicine approaches across diverse healthcare systems.

FYR Partners with Mayo Clinic to Develop Blood-Based Biomarkers for Parkinson's Disease Using AI-Enabled Platform

AIPrecision Medicine
  • FYR and Mayo Clinic have entered a collaboration to advance blood-based biomarker research for Parkinson's disease using FYR's AI-enabled EV-Omics platform.
  • The partnership aims to identify biomarkers associated with Parkinson's disease progression and subtypes by analyzing extracellular vesicles from blood samples.
  • FYR's technology enriches brain-derived extracellular vesicles to enhance detection of disease-associated proteins, RNA, and DNA for improved patient outcomes.
  • The collaboration seeks to develop innovative tools that could improve clinical trial results and advance precision care for Parkinson's patients.

Novel AI Model PROGRxN-BCa Significantly Improves NMIBC Progression Risk Prediction

AIOncologyPrecision Medicine
  • A new artificial intelligence model, PROGRxN-BCa, trained on over 12,000 patients, outperforms current guideline-endorsed risk calculators for non-muscle invasive bladder cancer progression by approximately 10%.
  • The model effectively sub-stratifies the heterogeneous intermediate-risk NMIBC patient group into distinct risk tertiles, enabling more personalized treatment approaches based on progression probability.
  • Developed using 14 readily available clinicopathological features, PROGRxN-BCa requires no specialized biomarkers or histopathological slides, making it practical for routine clinical implementation.

City of Hope to Present Groundbreaking Cancer Research at AACR Annual Meeting 2025

AIOncologyMonoclonal AntibodyPrecision Medicine
  • City of Hope researchers will present over 74 sessions at the AACR Annual Meeting 2025, showcasing innovative work in AI, precision medicine, and immunotherapies for various cancers.
  • A phase 3 clinical trial led by Dr. Aditya Shreenivas demonstrated that penpulimab combined with chemotherapy significantly improved progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
  • Novel AI tools and spatial transcriptomic technologies developed at City of Hope are advancing precision medicine approaches and revealing unique genetic changes in early-onset colorectal cancer among Hispanic and Latino patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.